Logo image of XENT

INTERSECT ENT INC (XENT) Stock Fundamental Analysis

USA - NASDAQ:XENT - US46071F1030 - Common Stock

28.24
0 (0%)
Last: 5/12/2022, 8:00:03 PM
28.24
0 (0%)
After Hours: 5/12/2022, 8:00:03 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to XENT. XENT was compared to 188 industry peers in the Health Care Equipment & Supplies industry. XENT has a bad profitability rating. Also its financial health evaluation is rather negative. XENT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year XENT has reported negative net income.
XENT Yearly Net Income VS EBIT VS OCF VS FCFXENT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -50M -100M -150M

1.2 Ratios

Industry RankSector Rank
ROA -132.19%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XENT Yearly ROA, ROE, ROICXENT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 100 -100 200

1.3 Margins

Industry RankSector Rank
OM -75.06%
PM (TTM) -161.94%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XENT Yearly Profit, Operating, Gross MarginsXENT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 50 -50 -100

More info and screens

1

2. Health

2.1 Basic Checks

XENT has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, XENT has a worse debt to assets ratio.
XENT Yearly Shares OutstandingXENT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M
XENT Yearly Total Debt VS Total AssetsXENT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -5.47, we must say that XENT is in the distress zone and has some risk of bankruptcy.
A Debt/Equity ratio of -1.52 indicates that XENT is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity -1.52
Debt/FCF N/A
Altman-Z -5.47
ROIC/WACCN/A
WACCN/A
XENT Yearly LT Debt VS Equity VS FCFXENT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 1.88 indicates that XENT should not have too much problems paying its short term obligations.
A Quick Ratio of 1.50 indicates that XENT should not have too much problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.88
Quick Ratio 1.5
XENT Yearly Current Assets VS Current LiabilitesXENT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 50M 100M

More info and screens

4

3. Growth

3.1 Past

XENT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -120.27%.
The Revenue has grown by 22.25% in the past year. This is a very strong growth!
The Revenue has been growing slightly by 6.29% on average over the past years.
EPS 1Y (TTM)-120.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-63.46%
Revenue 1Y (TTM)22.25%
Revenue growth 3Y-0.54%
Revenue growth 5Y6.29%
Sales Q2Q%-11.34%

3.2 Future

XENT is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.25% yearly.
Based on estimates for the next years, XENT will show a quite strong growth in Revenue. The Revenue will grow by 19.06% on average per year.
EPS Next Y37%
EPS Next 2Y17.73%
EPS Next 3Y8.55%
EPS Next 5Y3.25%
Revenue Next Year14.26%
Revenue Next 2Y19.58%
Revenue Next 3Y18.84%
Revenue Next 5Y19.06%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
XENT Yearly Revenue VS EstimatesXENT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
XENT Yearly EPS VS EstimatesXENT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XENT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XENT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XENT Price Earnings VS Forward Price EarningsXENT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -14.14
XENT Per share dataXENT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.73%
EPS Next 3Y8.55%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XENT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTERSECT ENT INC

NASDAQ:XENT (5/12/2022, 8:00:03 PM)

After market: 28.24 0 (0%)

28.24

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-04 2022-05-04/amc
Earnings (Next)08-04 2022-08-04
Inst Owners3.42%
Inst Owner Change0%
Ins Owners10.56%
Ins Owner ChangeN/A
Market Cap954.79M
Revenue(TTM)103.99M
Net Income(TTM)-168.40M
Analysts45.71
Price Target28.82 (2.05%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.18
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA -14.14
EPS(TTM)-5.03
EYN/A
EPS(NY)-1.1
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS3.08
BVpS-2.78
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -132.19%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -75.06%
PM (TTM) -161.94%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity -1.52
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.88
Quick Ratio 1.5
Altman-Z -5.47
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-120.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-63.46%
EPS Next Y37%
EPS Next 2Y17.73%
EPS Next 3Y8.55%
EPS Next 5Y3.25%
Revenue 1Y (TTM)22.25%
Revenue growth 3Y-0.54%
Revenue growth 5Y6.29%
Sales Q2Q%-11.34%
Revenue Next Year14.26%
Revenue Next 2Y19.58%
Revenue Next 3Y18.84%
Revenue Next 5Y19.06%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

INTERSECT ENT INC / XENT FAQ

Can you provide the ChartMill fundamental rating for INTERSECT ENT INC?

ChartMill assigns a fundamental rating of 2 / 10 to XENT.


Can you provide the valuation status for INTERSECT ENT INC?

ChartMill assigns a valuation rating of 0 / 10 to INTERSECT ENT INC (XENT). This can be considered as Overvalued.


Can you provide the profitability details for INTERSECT ENT INC?

INTERSECT ENT INC (XENT) has a profitability rating of 1 / 10.


How financially healthy is INTERSECT ENT INC?

The financial health rating of INTERSECT ENT INC (XENT) is 2 / 10.